The peritoneal cavity provides a protective niche for B1 and conventional B lymphocytes during anti-CD20 immunotherapy in mice

Journal of Immunology

Volumn 174, Issue 7, 2005, Pages 4389-4399

  Hamaguchi, Yasuhito ^a   Uchida, Junji ^a   Cain, Derek W ^a   Venturi, Guglielmo M ^a   Poe, Jonathan C ^a   Haas, Karen M ^a   Tedder, Thomas F ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIBODY; CD20 ANTIGEN; COMPLEMENT COMPONENT C3; FC RECEPTOR;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; AUTOIMMUNE DISEASE; B LYMPHOCYTE; BLOOD; BONE MARROW; CELL MATURATION; CELL MIGRATION; EFFECTOR CELL; IMMUNOTHERAPY; IN VIVO STUDY; INFLAMMATION; INNATE IMMUNITY; INTESTINE LYMPHATIC TISSUE; LYMPH NODE; LYMPHOMA; MONOCYTE; MOUSE; NONHUMAN; PERITONEAL CAVITY; PRIORITY JOURNAL; SPLEEN;

EID: 15444368773     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.174.7.4389     Document Type: Article

References (52)

1. Tedder, T. F., and P. Engel. 1994. CD20: a regulator of cell-cycle progression of B lymphocytes. Immunol. Today 15:450.
2. Press, O. W., J. P. Leonard, B. Coiffier, R. Levy, and J. Timmerman. 2001. Immunotherapy of non-Hodgkin's lymphomas. Hematology 2001:221.
3. 131I]anti-B1 (anti-CD20) antibody. N. Engl. J. Med. 329:459.
4. Weiner, L. M. 1999. Monoclonal antibody therapy of cancer. Semin. Oncol. 26:43.
5. Onrust, S. V., H. M. Lamb, and J. A. Balfour. 1999. Rituximab. Drugs 58:79.
6. McLaughlin, P., C. A. White, A. J. Grillo-Lopez, and D. G. Maloney. 1998. Clinical status and optimal use of Rituximab for B-cell lymphomas. Oncology 12:1763.
7. Reff, M. E., K. Carner, K. S. Chambers, P. C. Chinn, J. E. Leonard, R. Raab, R. A. Newman, and N. Hanna. 1994. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83:435.
8. Maloney, D. G., A. J. Grillo-L'opez, C. A. White, D. Bodkin, R. J. Schilder, J. A. Neidhart, N. Janakiraman, K. A. Foon, T. M. Liles, B. K. Dallaire, et al. 1997. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 90:2188.
9. Maloney, D. G., L. A. Grillo, D. J. Bodkin, C. A. White, T. M. Liles, I. Royston, C. Varns, J. Rosenberg, and R. Levy. 1997. IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J. Clin. Oncol. 15:3266.
10. Silverman, G. J., and S. Weisman. 2002. Rituximab therapy and autoimmune disorders: prospects for anti-B cell therapy. Arthritis Rheum. 48:1484.
11. Edwards, J. C. W., and G. Cambridge. 2001. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology 40:1.
12. Patel, D. D. 2002. B cell-ablative therapy for the treatment of autoimmune diseases. Arthritis Rheum. 46:1984.
13. Smith, M. R. 2003. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene 22:7359.
14. Demidem, A., T. Lam, S. Alas, K. Hariharan, H. Hanna, and B. Bonavida. 1997. Chimeric anti-CD20 antibody (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother. Radiopharm. 12:177.
15. Shan, D., J. A. Ledbetter, and O. W. Press. 1998. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood 91:1644.
16. Golay, J., M. Lazzari, V. Facchinetti, S. Bernasconi, O. Borleri, T. Barbui, A. Rambaldi, and M. Introna. 2001. CD20 levels determine the in vitro susceptibility to Rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59. Blood 98:3383.
17. Cragg, M. S., S. M. Morgan, H. T. Chan, B. P. Morgan, A. V. Falatov, P. W. Johnson, R. R. French, and M. J. Glennie. 2003. Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. Blood 101:1045.
18. Di Gaetano, N., E. Cittera, R. Nota, A. Vecchi, V. Grieco, E. Scanziani, M. Botto, M. Introna, and J. Golay. 2003. Complement activation determines the therapeutic activity of Rituximab in vivo. J. Immunol. 171:1581.
19. Van der Kolk, L. E., A. J. Grillo-López, J. W. Baars, C. E. Hack, and M. H. J. van Oers. 2001. Complement activation plays a key role in the side-effects of Rituximab treatment. Br. J. Haematol. 115:807.
20. Weng, W.-K., and R. Levy. 2001. Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after Rituximab treatment in follicular non-Hodgkin lymphoma. Blood 98:1352.
21. Clynes, R. A., T. L. Towers, L. G. Presta, and J. V. Ravetch. 2000. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med. 6:443.
22. Uchida, J., Y. Lee, M. Hasegawa, Y. Liang, A. Bradney, J. A. Oliver, K. Bowen, D. A. Steeber, K. M. Haas, J. C. Poe, and T. F. Tedder. 2004. Mouse CD20 expression and function. Int. Immunol. 16:119.
23. Uchida, J., Y. Hamaguchi, J. A. Oliver, J. V. Ravetch, J. C. Poe, K. M. Haas, and T. F. Tedder. 2004. The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J. Exp. Med. 199:1659.
24. Sato, S., N. Ono, D. A. Steeber, D. S. Pisetsky, and T. F. Tedder. 1996. CD19 regulates B lymphocyte signaling thresholds critical for the development of B-1 lineage cells and autoimmunity. J. Immunol. 157:4371.
25. + T cells that secrete IFN-γ and IL-5. J. Immunol. 145:68.
26. Engel, P., L.-J. Zhou, D. C. Ord, S. Sato, B. Koller, and T. F. Tedder. 1995. Abnormal B lymphocyte development, activation and differentiation in mice that lack or overexpress the CD19 signal transduction molecule. Immunity 3:39.
27. Wessels, M. R., P. Butko, M. Ma, H. B. Warren, A. Lage, and M. C. Carroll. 1995. Studies of group B streptococcal infection in mice deficient in complement C3 or C4 demonstrate an essential role for complement in both innate and acquired immunity. Proc. Natl. Acad. Sci. USA 92:11490.
28. Denkers, E. Y., C. C. Badger, J. A. Ledbetter, and I. D. Bernstein. 1985. Influence of antibody isotype on passive serotherapy of lymphoma. J. Immunol. 135:2183.
29. Vieira, P., and K. Rajewsky. 1988. The half-lives of serum immunoglobulins in adult mice. Eur. J. Immunol. 18:313.
30. Maloney, D. G., T. M. Liles, D. K. Czerwinski, C. Waldichuk, J. Rosenberg, A. Grillo-Lopez, and R. Levy. 1994. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antobody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 84:2457.
31. Takai, T., M. Li, D. Sylvestre, R. Clynes, and J. V. Ravetch. 1994. FcR γ chain depletion results in pleiotrophic effector cell defects. Cell 76:519.
32. Tedder, T. F., D. A. Steeber, and P. Pizcueta. 1995. L-selectin deficient mice have impaired leukocyte recruitment into inflammatory sites. J. Exp. Med. 181:2259.
33. Loder, F., B. Mutschler, R. J. Ray, C. J. Paige, P. Sideras, R. Torres, M. C. Lamers, and R. Carsetti. 1999. B cell development in the spleen takes place in discrete steps and is determined by the quality of B cell receptor-derived signals. J. Exp. Med. 190:75.
34. Martin, F., and J. F. Kearney. 2001. B1 cells: similarities and differences with other B cell subsets. Curr. Opin. Immunol. 13:195.
35. Hayakawa, K., M. Asano, S. A. Shinton, M. Gui, D. Allman, C. L. Stewart, J. Silver, and R. R. Hardy. 1999. Positive selection of natural autoreactive B cells. Science 285:113.
36. Lalor, P. A., L. A. Herzenberg, S. Adams, and A. M. Stall. 1989. Feedback regulation of muring Ly-1 B cell development. Eur. J. Immunol. 19:507.
37. Deenen, G. J., and F. G. M. Kroese. 1993. Kinetics of peritoneal B-1a cells (CD5 B cells) in young adult mice. Eur. J. Immunol. 23:12.
38. Rozman, C., and E. Montserrat. 1995. Chronic lymphocytic leukemia. N. Engl. J. Med. 333:1052.
39. Byrd, J. C., T. Murphy, R. S. Howard, M. S. Lucas, A. Goodrich, K. Park, M. Paerson, J. K. Waselenko, G. Ling, M. R. Grever, et al. 2001. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J. Clin. Oncol. 19:2153.
40. O'Brien, S. M., H. Kantarjian, D. A. Thomas, F. J. Giles, E. J. Freireich, J. Cortes, S. Lerner, and M. J. Keating. 2001. Rituximab dose-escalation trial in chronic lymphocytic leukemia. J. Clin. Oncol. 19:2165.
41. Farag, S. S., I. W. Flinn, R. Modali, T. A. Lehman, D. Young, and J. C. Byrd. 2004. FcγRIIIa and FcγRIIa polymorphisms do not predict response to Rituximab in B-cell chronic lymphocytic leukemia. Blood 103:1472.
42. Schroder, C., A. M. Azimzadeh, G. Wu, J. O. Price, J. B. Atkinson, and R. N. Pierson. 2003. Anti-CD20 treatment depletes B-cells in blood and lymphatic tissue of cynomolgus monkeys. Transplant Immunol. 12:19.
43. Igarashi, T., Y. Kobayashi, M. Ogura, T. Kinoshita, T. Ohtsu, Y. Sasaki, Y. Morishima, T. Murate, M. Kasai, N. Uike, et al. 2002. Factors affecting toxicity, response and progression-free survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with Rituximab: a Japanese phase II study. Ann. Oncol. 13:928.
44. McLaughlin, P., L. A. Grillo, B. K. Link, R. Levy, M. S. Czuczman, M. E. Williams, M. R. Heyman, B. I. Bence, C. A. White, F. Cabanillas, et al. 1998. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J. Clin. Oncol. 16:2825.
45. Raderer, M., G. Jager, S. Brugger, A. Puspok, W. Fiebiger, J. Drach, A. Wotherspoon, and A. Chott. 2003. Rituximab for treatment of advanced extranodal marginal zone B cell lymphoma of the mucosa-associated lymphoid tissue lymphoma. Oncology 65:306.
46. Perez, C. L., and S. Rudoy. 2001. Anti-CD20 monoclonal antibody treatment of human herpesvirus 8-associated, body cavity-based lymphoma with an unusual phenotype in a human immunodeficiency virus-negative patient. Clin. Diagn. Lab. Immunol. 8:993.
47. Takao, T., Y. Kobayashi, J. Kuroda, A. Omoto, T. Nishimura, Y. Kamitsuji, E. Fukiya, C. Nakamura, S. Kimura, and T. Yoshikawa. 2004. Rituximab is effective for human herpesvirus-8-negative primary effusion lymphoma with CD20 phenotype associated hepatitis C virus-related liver cirrhosis. Am. J. Hematol. 77:419.
48. Winkler, U., M. Jensen, O. Manzke, H. Schulz, V. Diehl, and A. Engert. 1999. Cytokine-release syndrome in patients with B cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (Rituximab, IDEC-C2B8). Blood 94:2217.
49. Alwayn, I. P. J., Y. Xu, M. Basker, C. Wu, L. Buhler, D. Lambrigts, S. Treter, D. Harper, H. Kitamura, E. S. Vitetta, et al. 2001. Effects of specific anti-B and/or anti-plasma cell immunotherapy on antibody production in baboons: depletion of CD20- and CD22-positive B cells does not result in significantly decreased production of anti-αGal antibody. Xenotransplantation 8:157.
50. Vugmeyster, Y., K. Howell, K. McKeever, D. Combs, and E. Canova-Davis. 2003. Differential in vivo effects of Rituximab on two B-cell subsets in cynomolgus monkeys. Int. Immunopharmacol. 3:1477.
51. Martin, F., and A. C. Chan. 2004. Pathogenic roles of B cells in human autoimmunity: insights from the clinic. Immunity 20:517.
52. Coiffier, B., C. Haioun, N. Ketterer, A. Engert, H. Tilly, D. Ma, P. Johnson, A. Lister, M. Feuring-Buske, J. A. Radford, et al. 1998. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 92:1927.